Genmab A/S (GMAB) Reports 2021 Net Sales of DARZALEX of $6.02B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
January 25, 2022 6:30 AM ESTCompany Announcement
Net sales of DARZALEX® in 2021 totaled USD 6,023 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc.Copenhagen, Denmark; January 25, 2022 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab),... More
